Welcome to our dedicated page for Jade Biosciences news (Ticker: JBIO), a resource for investors and traders seeking the latest updates and insights on Jade Biosciences stock.
Jade Biosciences, Inc. (Nasdaq: JBIO) is a clinical-stage biotechnology company developing monoclonal antibody therapies for autoimmune diseases, and its news flow reflects progress across this pipeline. Company press releases highlight clinical development updates, preclinical data presentations, financing events, and corporate milestones that are relevant to investors and followers of autoimmune drug development.
A central theme in Jade’s news is the advancement of JADE101, its fully human monoclonal antibody that selectively blocks APRIL for the treatment of immunoglobulin A nephropathy (IgAN). Updates include initiation of a Phase 1 healthy volunteer trial, expectations for interim biomarker-rich data, and presentations of preclinical safety and translational biomarker analyses at scientific meetings such as the American Society of Nephrology Kidney Week. These items provide insight into how the company is using pharmacokinetic and biomarker data to guide later-stage studies.
News items also cover JADE201, a half-life extended, afucosylated anti-BAFF-R monoclonal antibody in preclinical development for autoimmune diseases. Announcements describe its preclinical profile in non-human primates, the rationale for targeting BAFF-R, and plans for a first-in-human trial in rheumatoid arthritis with biomarker-focused endpoints.
In addition to pipeline updates, Jade Biosciences issues releases on private placements and PIPE financings, detailing expected gross proceeds, investor participation, and intended use of funds for research and development and corporate purposes. Corporate news can also include participation in healthcare and investor conferences, where the company presents overviews and outlooks. Together, these news categories give readers a view into Jade’s scientific progress, clinical timelines, capital strategy, and visibility within the biotechnology and healthcare investment community.
For those tracking JBIO, following this news stream can help monitor key milestones for JADE101 and JADE201, financing activities, and other developments that the company discloses through press releases and related communications.
Jade Biosciences (Nasdaq: JBIO) reported Q4 and full‑year 2025 results and provided a corporate update on its autoimmune pipeline and financing.
Key items: $336.2 million cash and investments as of December 31, 2025, expected runway into the first half of 2028; JADE101 Phase 1 interim data expected Q2 2026; JADE101 Phase 2 in IgA nephropathy to start mid‑2026 with preliminary 2027 data; JADE201 first‑in‑human trial to begin Q2 2026; JADE301 nominated with Phase 1 planned H1 2027; completed private financings raising ~$180 million.
Jade Biosciences (Nasdaq: JBIO) will participate in multiple investor conferences in late February and March 2026, including Oppenheimer, TD Cowen, Leerink, and Jefferies.
Management will present, host fireside chats, and hold one-on-one investor meetings. According to the company, live webcasts will be available on the Events & Presentations page with replays archived for 90 days.
Jade Biosciences (Nasdaq: JBIO) outlined 2026 objectives to advance a pipeline of monoclonal antibodies across autoimmune diseases and will present at the J.P. Morgan Healthcare Conference on January 15, 2026.
Key program milestones include JADE101 Phase 1 interim biomarker data in H1 2026 and a planned Phase 2 start in mid-2026 for IgA nephropathy; JADE201 first-in-human start in Q2 2026 with interim data expected in 2027; and nominated JADE301 entering first-in-human study in H1 2027. The company reported approximately $336 million cash and investments as of December 31, 2025, expected to fund operations into H1 2028.
Jade Biosciences (Nasdaq: JBIO) entered a securities purchase agreement with BB Biotech for a $45 million private placement, selling 3,214,286 shares of common stock at $14.00 per share. The private placement is expected to close on or about December 16, 2025, subject to customary closing conditions.
The company said it intends to use net proceeds to fund research and development, general corporate expenses, and working capital. The sale is a private transaction and the shares are unregistered; Jade agreed to file a registration statement with the SEC to register resale of the shares under a registration rights agreement.
Jade Biosciences (Nasdaq: JBIO) reported Q3 2025 results and a corporate update on Nov 13, 2025 highlighting clinical advances and financing.
Key points: presented favorable preclinical safety and translational biomarker data for JADE101 at ASN Kidney Week; initiated a Phase 1 healthy volunteer study with interim biomarker-rich data expected in H1 2026; unveiled JADE201, an afucosylated anti-BAFF-R candidate with first-in-human RA trial planned in H1 2026; completed a $135 million private placement and reported pro forma cash of approximately $325.6 million, funding operations into the first half of 2028.
Jade Biosciences (Nasdaq: JBIO) presented two posters at ASN Kidney Week 2025 on JADE101, an investigational anti-APRIL monoclonal antibody for IgA nephropathy (IgAN).
Key highlights: preclinical NHP safety showed a NOAEL at highest GLP dose, no off-target binding across >6,000 human proteins, no tissue cross-reactivity, and preserved vaccine responses. JADE101 produced reversible IgA reductions ~55–68% and IgM reductions ~62–75% (IgG reductions ~35–48%).
A Phase 1 healthy volunteer trial is ongoing with interim biomarker data expected in first half of 2026; translational analyses reported strong correlations between healthy volunteer and patient biomarker responses (r values up to 0.96) supporting dose selection.
Jade Biosciences (Nasdaq: JBIO) will participate in multiple investor conferences in November 2025, including Wedbush Rewind ASN, Stifel Healthcare, TD Cowen Immunology & Inflammation Virtual Summit, and Jefferies Global Healthcare in London.
Scheduled events include a Wedbush fireside chat on Nov 10, 2025 at 12:40 p.m. ET, a Stifel presentation on Nov 12, 2025 at 4:00 p.m. ET, a TD Cowen presentation on Nov 13, 2025 at 3:00 p.m. ET, and a Jefferies presentation on Nov 17, 2025 at 3:30 p.m. GMT. Live webcasts and archived replays will be available on Jade Biosciences' Events & Presentations page for 90 days after each event.
Jade Biosciences (Nasdaq: JBIO) will present new preclinical safety and translational data for JADE101 at ASN Kidney Week 2025 in Houston, Nov 5–9, 2025. JADE101 is an anti-APRIL monoclonal antibody in development for immunoglobulin A nephropathy (IgAN) and is engineered for subcutaneous dosing based on differentiated preclinical PK/PD in non-human primates.
The company is conducting a Phase 1 healthy volunteer trial of JADE101, with interim data expected in the first half of 2026. Two poster presentations are scheduled on Nov 8, 2025, 10:00 AM–12:00 PM CT: SA-PO0255 (nonclinical safety) and SA-PO0272 (translational framework), presented by Ashley McCord and Brandon Gufford.
Jade Biosciences (Nasdaq: JBIO) announced JADE201, an investigational half-life extended, afucosylated monoclonal antibody targeting BAFF receptor for autoimmune diseases.
Preclinical non-human primate data showed dose-dependent BAFF-R occupancy, sustained B‑cell depletion after a single subcutaneous dose, and ~2x half-life versus ianalumab. JADE201 combines afucosylation for enhanced ADCC and an Fc mutation to extend systemic exposure while preserving activity.
A randomized, placebo-controlled, single-ascending-dose first-in-human trial in rheumatoid arthritis is expected to begin in H1 2026. The company will host a conference call and webcast on Oct 7, 2025 at 8:00 a.m. ET.
Jade Biosciences (Nasdaq: JBIO) announced a private placement expected to raise approximately $135 million in gross proceeds via a PIPE financing, subject to customary closing conditions with an expected close on or about October 8, 2025. The transaction sells 13,368,164 shares at $9.14 and 1,402,092 pre-funded warrants at $9.1399 each (exercise price $0.0001).
After issuance, there will be about 67.4 million shares and equivalents outstanding. The company said net proceeds plus existing cash are expected to fund operations into 1H 2028. Placement agents and a registration rights agreement were disclosed.